159992 创新药
已收盘 11-09 15:00:00
资讯
新帖
简况
生物医药板块走强 再鼎医药（09688）涨超13% 全球医药融资回暖支撑创新药与CXO景气上行
金吾财讯 · 10:08
生物医药板块走强 再鼎医药（09688）涨超13% 全球医药融资回暖支撑创新药与CXO景气上行
创新药概念震荡反弹
第一财经 · 10:04
创新药概念震荡反弹
股市必读：以岭药业新发布《关于中药创新药小儿连花感冒颗粒获得药品注册证书的公告》
证券之星 · 01:54
股市必读：以岭药业新发布《关于中药创新药小儿连花感冒颗粒获得药品注册证书的公告》
直击进博会：25家药企借力AI布局商保准入 创新药被“精算”重新标价
每日经济新闻 · 11-08 21:33
直击进博会：25家药企借力AI布局商保准入 创新药被“精算”重新标价
镁信健康进博会推出AI商保准入平台 探索创新药商业化新路径
同花顺 · 11-08 21:31
镁信健康进博会推出AI商保准入平台 探索创新药商业化新路径
镁信健康进博会推出AI商保准入平台 探索创新药商业化新路径
证券日报 · 11-08 21:25
镁信健康进博会推出AI商保准入平台 探索创新药商业化新路径
药险博弈进入“一保一策”阶段，创新药企探寻商保对话路径
第一财经 · 11-08 19:13
药险博弈进入“一保一策”阶段，创新药企探寻商保对话路径
进博会观察｜创新药热潮中的支付变局，如何打开商保准入的增量空间？
蓝鲸财经 · 11-08 10:11
进博会观察｜创新药热潮中的支付变局，如何打开商保准入的增量空间？
维升药业携手卓正医疗深化战略合作 拓展创新药商业化服务生态
同花顺 · 11-07 22:39
维升药业携手卓正医疗深化战略合作 拓展创新药商业化服务生态
诺华携免疫领域在研创新药亮相第九届进博会
同花顺 · 11-06 22:39
诺华携免疫领域在研创新药亮相第九届进博会
创新药对外技术授权达1300亿美元！研发重心前移，药械巨头进博会加码本土化
时代周报 · 11-06 17:18
创新药对外技术授权达1300亿美元！研发重心前移，药械巨头进博会加码本土化
研报掘金｜浙商证券：维持众生药业“买入”评级，创新药逐步形成第二增长曲线
格隆汇 · 11-06
研报掘金｜浙商证券：维持众生药业“买入”评级，创新药逐步形成第二增长曲线
博安生物盘中涨超5%，创新药获批临床及产品出海授权
同花顺 · 11-06
博安生物盘中涨超5%，创新药获批临床及产品出海授权
生物制品概念盘中走弱，2026Q3创新药在医药板块内持仓占比降至43%|异动情报
东方财富网 · 11-06
生物制品概念盘中走弱，2026Q3创新药在医药板块内持仓占比降至43%|异动情报
武田制药发作性睡病创新药进博首秀，展示全球研发管线最新进展
同花顺 · 11-06
武田制药发作性睡病创新药进博首秀，展示全球研发管线最新进展
11月6日每日研选丨创新药迎来业绩兑现期 产业链投资机会持续显现
东方财富网 · 11-06
11月6日每日研选丨创新药迎来业绩兑现期 产业链投资机会持续显现
股市必读：奥赛康新发布《关于公司创新药奥美妥塔单抗上市许可申请获得受理的公告》
证券之星 · 11-06
股市必读：奥赛康新发布《关于公司创新药奥美妥塔单抗上市许可申请获得受理的公告》
A股现积极企稳信号 机构看好AI 产业链与创新药机遇
东方财富网 · 11-05
A股现积极企稳信号 机构看好AI 产业链与创新药机遇
创新药龙头，净利大增超400%！今年3次上调业绩预期
同花顺 · 11-05
创新药龙头，净利大增超400%！今年3次上调业绩预期
CRO订单从哪来：创新药BD交易结构升级如何改写研发外包需求
同花顺 · 11-05
CRO订单从哪来：创新药BD交易结构升级如何改写研发外包需求
公司概况
公司名称：
--
所属市场：
上市日期：
--
主营业务：
发行价格：
--
{"stockData":{"symbol":"159992","market":"SZ","secType":"STK","nameCN":"创新药","latestPrice":0.832,"timestamp":1794207831000,"preClose":0.837,"halted":0,"volume":479680250,"delay":0,"changeRate":-0.006,"floatShares":0,"shares":0,"eps":0,"marketStatus":"已收盘","change":-0.005,"latestTime":"11-09 15:00:00","open":0.841,"high":0.847,"low":0.831,"amount":402000000,"amplitude":0.0191,"askPrice":0.833,"askSize":17876,"bidPrice":0.832,"bidSize":17863,"shortable":0,"etf":1,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1794274200000},"marketStatusCode":5,"adr":0,"adjPreClose":0.837,"symbolType":"fund","openAndCloseTimeList":[[1794187800000,1794195000000],[1794200400000,1794207600000]],"highLimit":0.921,"lowLimit":0.753,"ibTradeSell":false,"ibTradeBuySell":true,"isCdr":false,"pbRate":0,"committee":0.522983,"marketValue":0,"turnoverRate":0,"status":1,"floatMarketCap":0},"requestUrl":"/m/hq/s/159992/wiki","defaultTab":"wiki","newsList":[{"id":"2682820601","title":"生物医药板块走强 再鼎医药（09688）涨超13% 全球医药融资回暖支撑创新药与CXO景气上行","url":"https://stock-news.laohu8.com/highlight/detail?id=2682820601","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2682820601?lang=zh_cn&edition=full","pubTime":"2026-11-09 10:08","pubTimestamp":1794190084,"startTime":"0","endTime":"0","summary":"金吾财讯 | 生物医药板块走强，截至发稿，再鼎医药 涨13.07%，康诺亚-B涨7.22%，康方生物涨6.33%，科伦博泰生物涨5.36%，药明生物涨4.96%，金斯瑞生物科技涨4.48%，复宏汉霖涨4.04%。2026年上半年，全球生物科技融资、License交易、并购交易金额分别达到502亿美元、1667亿美元和960亿美元，均显著超越去年上半年，医药融资及License交易持续回暖，为医药研发提供了资金支持。","market":"sg","thumbnail":"https://static.szfiu.com/news/20241108/OTEzM2QyMzQzMjc2MzA3OTk2MA==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/OTEzM2QyMzQzMjc2MzA3OTk2MA==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"299f0a9977df499f8ead781071e5e5e7","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1995489","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06990","09939","WX","159938","06978","BK1610","BK1588","LU0181495838.USD","LU0029874061.USD","399441","LU0456827905.SGD","LU0516423091.SGD","LU1794554557.SGD","LU0561508036.HKD","LU0051755006.USD","IBBQ","XBI","KURE","BK1574","BK4581","LU2476274308.USD","MEDX","159992","01548","02162","LU0348767384.USD","LU0456846285.SGD","LU0140636845.USD","LU0348825331.USD","LU2039709279.SGD","ZLAB","LU0543330566.HKD","LU0196878994.USD","CXO","BK4588","161726","09688","LU0359201612.USD","LU0320764243.SGD","LU1242518857.USD","LNGR","SG9999002562.SGD","HK0000165453.HKD","BK1583","LU1242518931.SGD","LU0348784397.USD","02269","09926","02696"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2682582099","title":"创新药概念震荡反弹","url":"https://stock-news.laohu8.com/highlight/detail?id=2682582099","media":"第一财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2682582099?lang=zh_cn&edition=full","pubTime":"2026-11-09 10:04","pubTimestamp":1794189889,"startTime":"0","endTime":"0","summary":"创新药概念震荡反弹","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202611093926036094.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202611093926036094.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["159992","LNGR","06978","MEDX","BK1161","BK1574","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2682251538","title":"股市必读：以岭药业新发布《关于中药创新药小儿连花感冒颗粒获得药品注册证书的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2682251538","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2682251538?lang=zh_cn&edition=full","pubTime":"2026-11-09 01:54","pubTimestamp":1794160456,"startTime":"0","endTime":"0","summary":"截至2026年11月6日收盘，以岭药业报收于16.05元，下跌0.37%，换手率0.94%，成交量12.9万手，成交额2.07亿元。当日关注点交易信息汇总：11月6日主力资金净流出1343.36万元，占总成交额6.48%。公司公告汇总：以岭药业收到国家药监局签发的小儿连花感冒颗粒《药品注册证书》，药品注册分类为中药1.1类，适用于4～12岁儿童风热感冒。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026110900000548.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","002603","BK1574","06978","BK0046","BK0097","BK0239","159992","BK0042","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681828168","title":"直击进博会：25家药企借力AI布局商保准入 创新药被“精算”重新标价","url":"https://stock-news.laohu8.com/highlight/detail?id=2681828168","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2681828168?lang=zh_cn&edition=full","pubTime":"2026-11-08 21:33","pubTimestamp":1794144838,"startTime":"0","endTime":"0","summary":"在第九届进博会医药展馆内，一款名为舒瑞基奥仑赛注射液（商品名：恺力美）吸引不少观众驻足。这是全球首款获批用于实体瘤的CAR-T细胞治疗产品，适用于CLDN18.2阳性、HER2阴性、经至少二线治疗失败的晚期胃/食管胃结合部腺癌。该产品单次制备定价99万元。“价格确实不低，但目前已经有多款商业保险可以报销。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://insurance.eastmoney.com/a/202611083925664540.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://insurance.eastmoney.com/a/202611083925664540.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1574","AIPO","159992","VTHR","LNGR","AGIX","BK1161","QTOC","MEDX","IBBQ","ARTY","06978","CHAT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681828909","title":"镁信健康进博会推出AI商保准入平台 探索创新药商业化新路径","url":"https://stock-news.laohu8.com/highlight/detail?id=2681828909","media":"同花顺","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2681828909?lang=zh_cn&edition=full","pubTime":"2026-11-08 21:31","pubTimestamp":1794144660,"startTime":"0","endTime":"0","summary":" 当人工智能(AI)遇上创新药市场准入，会带来怎样的变化？第九届中国国际进口博览会(以下简称“进博会”)期间，上海镁信健康科技集团股份有限公司(以下简称“镁信健 ...","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun","url":"http://stock.10jqka.com.cn/hks/20261108/c681583587.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/hks/20261108/c681583587.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["159992"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681828111","title":"镁信健康进博会推出AI商保准入平台 探索创新药商业化新路径","url":"https://stock-news.laohu8.com/highlight/detail?id=2681828111","media":"证券日报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2681828111?lang=zh_cn&edition=full","pubTime":"2026-11-08 21:25","pubTimestamp":1794144300,"startTime":"0","endTime":"0","summary":"当人工智能（AI）遇上创新药市场准入，会带来怎样的变化？第九届中国国际进口博览会（以下简称“进博会”）期间，上海镁信健康科技集团股份有限公司（以下简称“镁信健康”）宣布将旗下商业健康保险数据洞察平台InsRx.com升级为InsRx.ai，推出专门面向药企商业保险（以下简称“商保”）准入团队的AI工作平台。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202611083925664324.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202611083925664324.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["ARTY","06978","IBBQ","AGIX","159992","VTHR","CHAT","MEDX","LNGR","BK1161","AIPO","BK1574","QTOC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681409778","title":"药险博弈进入“一保一策”阶段，创新药企探寻商保对话路径","url":"https://stock-news.laohu8.com/highlight/detail?id=2681409778","media":"第一财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2681409778?lang=zh_cn&edition=full","pubTime":"2026-11-08 19:13","pubTimestamp":1794136397,"startTime":"0","endTime":"0","summary":"药企准入团队由此可能陷入新困境：没有统一目录，只有“一保一策”。商保市场信息散、规则乱、多疾病领域的保险责任与支付条件相互交叉，导致准入机会难筛、优先级难排。一位受访药企人士曾提到，新药上市后要“逐城跑惠民保，同步盯地方惠民保特药目录与国家商保创新药目录变动”。商保，正在接棒成为创新药商业化的重要支付端。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://insurance.eastmoney.com/a/202611083925646040.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://insurance.eastmoney.com/a/202611083925646040.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["159992","BK1161","BK1574","IBBQ","LNGR","06978","MEDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681849521","title":"进博会观察｜创新药热潮中的支付变局，如何打开商保准入的增量空间？","url":"https://stock-news.laohu8.com/highlight/detail?id=2681849521","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2681849521?lang=zh_cn&edition=full","pubTime":"2026-11-08 10:11","pubTimestamp":1794103885,"startTime":"0","endTime":"0","summary":"共识之一是，作为“医药险”闭环中的关键“支付方”，商业保险正成为创新药拓展增量空间的重要领域。进博会期间，武田中国总裁刘燕在主题活动的圆桌论坛中提出。作为重要的支付方，商业保险的推陈出新受到关注。进博会期间，镁信健康升级推出为创新药商保准入打造的AI工作台InsRx.ai。目前，强生创新制药、百时美施贵宝、百济神州、再鼎医药等国内外药企已入驻，已有超过25家药企正在使用InsRx.ai赋能其商保准入布局。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1794059379023185847","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["BK1161","IBBQ","LNGR","06978","159992","MEDX","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681106008","title":"维升药业携手卓正医疗深化战略合作 拓展创新药商业化服务生态","url":"https://stock-news.laohu8.com/highlight/detail?id=2681106008","media":"同花顺","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2681106008?lang=zh_cn&edition=full","pubTime":"2026-11-07 22:39","pubTimestamp":1794062340,"startTime":"0","endTime":"0","summary":"上证报中国证券网讯(记者邓贞)11月7日，在第九届中国国际进口博览会(以下简称“进博会”)上，专注于内分泌相关治疗领域的创新型生物医药公司维升药业与卓正医疗共同举行“维臻高®定点 ...","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun","url":"http://stock.10jqka.com.cn/hks/20261107/c681579820.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/hks/20261107/c681579820.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["159992"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681605088","title":"诺华携免疫领域在研创新药亮相第九届进博会","url":"https://stock-news.laohu8.com/highlight/detail?id=2681605088","media":"同花顺","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2681605088?lang=zh_cn&edition=full","pubTime":"2026-11-06 22:39","pubTimestamp":1793975940,"startTime":"0","endTime":"0","summary":"上证报中国证券网讯(记者严曦梦)在第九届中国国际进口博览会(以下简称“进博会”)上，全球创新药物公司诺华以“创所未见”为主题亮相。作为连续九届参展的进博“全勤生”，诺华今年再度携多 ...","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun","url":"http://stock.10jqka.com.cn/usstock/20261106/c681571759.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/usstock/20261106/c681571759.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["159992"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681985172","title":"创新药对外技术授权达1300亿美元！研发重心前移，药械巨头进博会加码本土化","url":"https://stock-news.laohu8.com/highlight/detail?id=2681985172","media":"时代周报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2681985172?lang=zh_cn&edition=full","pubTime":"2026-11-06 17:18","pubTimestamp":1793956698,"startTime":"0","endTime":"0","summary":"2025年以来，中国创新药行业迎来BD交易大爆发。这一势头在2026年持续，据国家发改委11月3日新闻发布会介绍，今年前三季度，创新药对外技术授权约1300亿美元，已接近去年全年水平。BD交易持续火热的背后，是跨国药企对中国创新药临床研发质量、速度与效率的系统性认可在加速兑现。这种认可并未止步于“买管线”，而是正向跨国药械企业在华本土化布局纵深传导。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202611063924900248.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202611063924900248.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["IBBQ","MEDX","06978","159992","BK1161","LNGR","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681858505","title":"研报掘金｜浙商证券：维持众生药业“买入”评级，创新药逐步形成第二增长曲线","url":"https://stock-news.laohu8.com/highlight/detail?id=2681858505","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2681858505?lang=zh_cn&edition=full","pubTime":"2026-11-06 15:46","pubTimestamp":1793951210,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["601878","002317","BK0276","BK0188","BK0077","159992","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681837715","title":"博安生物盘中涨超5%，创新药获批临床及产品出海授权","url":"https://stock-news.laohu8.com/highlight/detail?id=2681837715","media":"同花顺","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2681837715?lang=zh_cn&edition=full","pubTime":"2026-11-06 15:13","pubTimestamp":1793949180,"startTime":"0","endTime":"0","summary":"11月6日，博安生物(06955.HK)盘中涨超5%，截至15时9分，涨5.20%，报3.035港元/股，成交额148.94万港元。消息面上，11月6日，博安生物宣布，其自主开发的1类创新药BA2201获中国国家药品监督 ...","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun","url":"http://stock.10jqka.com.cn/hks/20261106/c681547243.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/hks/20261106/c681547243.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["159992"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681100832","title":"生物制品概念盘中走弱，2026Q3创新药在医药板块内持仓占比降至43%|异动情报","url":"https://stock-news.laohu8.com/highlight/detail?id=2681100832","media":"东方财富网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2681100832?lang=zh_cn&edition=full","pubTime":"2026-11-06 14:50","pubTimestamp":1793947859,"startTime":"0","endTime":"0","summary":"11月6日，生物制品盘中下跌3.04%，相关成分股中，近岸蛋白（688137）下跌12.18%，百普赛斯（301080）下跌11.03%，义翘神州（301047）下跌8.70%，诺唯赞（688105）下跌7.49%，奥浦迈（688293）下跌6.39%。消息面上，2026Q3创新药在医药板块内持仓占比降至43%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"east_money_stock","url":"http://stock.eastmoney.com/news/11134,202611063924769861.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.eastmoney.com/news/11134,202611063924769861.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"east_money_stock","symbols":["159938","BK1574","BK1515","IBBQ","LNGR","06978","09939","MEDX","159992","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681836801","title":"武田制药发作性睡病创新药进博首秀，展示全球研发管线最新进展","url":"https://stock-news.laohu8.com/highlight/detail?id=2681836801","media":"同花顺","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2681836801?lang=zh_cn&edition=full","pubTime":"2026-11-06 12:20","pubTimestamp":1793938800,"startTime":"0","endTime":"0","summary":"新京报贝壳财经讯(记者丁爽)11月5日，第九届中国国际进口博览会(简称“进博会”)启幕。本届进博会，全球化生物制药企业武田制药将集中展示覆盖消化及炎症性疾并罕见并血液制品、肿瘤和神经 ...","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun","url":"http://stock.10jqka.com.cn/usstock/20261106/c681543319.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/usstock/20261106/c681543319.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["159992"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681588974","title":"11月6日每日研选丨创新药迎来业绩兑现期 产业链投资机会持续显现","url":"https://stock-news.laohu8.com/highlight/detail?id=2681588974","media":"东方财富网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2681588974?lang=zh_cn&edition=full","pubTime":"2026-11-06 07:49","pubTimestamp":1793922576,"startTime":"0","endTime":"0","summary":"创新药企业正迎来从“讲故事”到“交成绩单”的关键转变。随着三季报披露收官，一批创新药企业盈利能力明显改善，部分Biotech企业实现扭亏为盈。海外授权交易持续落地，核心产品加速放量，创新药行业正逐步进入业绩收获期。请看机构最新研判。从最新业绩来看，创新药板块基本面持续改善。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"east_money_stock","url":"http://finance.eastmoney.com/news/1354,202611063924126754.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/news/1354,202611063924126754.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"east_money_stock","symbols":["IBBQ","159992","LNGR","06978","BK1574","BK1161","MEDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681005531","title":"股市必读：奥赛康新发布《关于公司创新药奥美妥塔单抗上市许可申请获得受理的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2681005531","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2681005531?lang=zh_cn&edition=full","pubTime":"2026-11-06 01:55","pubTimestamp":1793901312,"startTime":"0","endTime":"0","summary":"公司公告汇总：子公司奥美妥塔单抗注射液的上市许可申请获国家药监局受理，拟用于CLDN18.2阳性晚期胃或胃食管交界处腺癌一线治疗。公司公告汇总关于公司创新药奥美妥塔单抗上市许可申请获得受理的公告北京奥赛康药业股份有限公司子公司江苏奥赛康生物医药有限公司收到国家药品监督管理局出具的《受理通知书》，奥美妥塔单抗注射液的境内生产药品注册上市许可申请获得受理。目前该药处于审评阶段，获批时间与结果存在不确定性。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026110600002080.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK1161","BK0028","06978","002755","159992","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681077764","title":"A股现积极企稳信号 机构看好AI 产业链与创新药机遇","url":"https://stock-news.laohu8.com/highlight/detail?id=2681077764","media":"东方财富网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2681077764?lang=zh_cn&edition=full","pubTime":"2026-11-05 23:35","pubTimestamp":1793892957,"startTime":"0","endTime":"0","summary":"新华财经上海11月5日电（记者魏雨田）近日A股市场止跌回升，三大股指收盘同步录得两连涨，沪深两市成交额连续两个交易日站稳2万亿元，市场呈现“量升价增”的向好信号。国联安基金分析认为，本轮市场大概率已经完成深度调整，筹码基本出清。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"east_money_stock","url":"http://stock.eastmoney.com/news/1407,202611053923896061.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.eastmoney.com/news/1407,202611053923896061.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"east_money_stock","symbols":["02827","07233","83130","83188","BK1610","BK1574","02843","AIPO","159982","399300","82822","QTOC","VTHR","ARTY","CHAT","82843","IBBQ","LNGR","02823","02846","03188","82846","MEDX","AGIX","03130","82823","159992","06978","BK1161","BK1147","02822"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681214075","title":"创新药龙头，净利大增超400%！今年3次上调业绩预期","url":"https://stock-news.laohu8.com/highlight/detail?id=2681214075","media":"同花顺","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2681214075?lang=zh_cn&edition=full","pubTime":"2026-11-05 21:20","pubTimestamp":1793884800,"startTime":"0","endTime":"0","summary":"百济神州今年第三次上调业绩预期。 A股总市值4227亿元的百济神州(688235)在披露三季报的同时，再次上调全年业绩预期。百济神州董事长、首席执行官欧雷强表示，这体现了公司全球业务的持续快 ...","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun_highlight","url":"http://news.10jqka.com.cn/20261105/c681523019.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://news.10jqka.com.cn/20261105/c681523019.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun_highlight","symbols":["159992","IBBQ","06978","BK1574","MEDX","LNGR","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681416970","title":"CRO订单从哪来：创新药BD交易结构升级如何改写研发外包需求","url":"https://stock-news.laohu8.com/highlight/detail?id=2681416970","media":"同花顺","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2681416970?lang=zh_cn&edition=full","pubTime":"2026-11-05 16:23","pubTimestamp":1793866980,"startTime":"0","endTime":"0","summary":"CRO板块的涨停潮把一个问题推到台前：当创新药BD交易从单一管线授权走向平台打包、Co-Co和NewCo，研发外包需求的类型和节奏究竟在发生什么变化？先看交易结构本身。普华永道中国医药医疗行 ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun_highlight","url":"http://news.10jqka.com.cn/20261105/c681506147.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://news.10jqka.com.cn/20261105/c681506147.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun_highlight","symbols":["BK1161","06978","MEDX","BK1574","159992","IBBQ","LNGR"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1794214031756,"stockEarnings":[{"period":"1week","weight":0.0662},{"period":"1month","weight":-0.0401},{"period":"3month","weight":-0.0802},{"period":"6month","weight":0.0145},{"period":"1year","weight":-0.0648},{"period":"ytd","weight":0.0072}],"compareEarnings":[{"period":"1week","weight":0.0139},{"period":"1month","weight":-0.0502},{"period":"3month","weight":-0.0738},{"period":"6month","weight":-0.127},{"period":"1year","weight":-0.0895},{"period":"ytd","weight":-0.0805}],"compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.53.0","shortVersion":"4.53.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"创新药(159992)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供创新药(159992)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"创新药,159992,创新药股票,创新药股票老虎,创新药股票老虎国际,创新药行情,创新药股票行情,创新药股价,创新药股市,创新药股票价格,创新药股票交易,创新药股票购买,创新药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"创新药(159992)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供创新药(159992)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}